AI-Driven Early Detection of Skin Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Smartphone-based AI skin lesion analysis (NuvanaDx platform)..
- Who it may be relevant to
- Registry conditions: Skin Cancer Melanoma. Basic parameters: from 18 months · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.
Detailed description
The study will collect retrospective and prospective anonymized skin lesion images and metadata to validate the AI algorithm against dermatology-confirmed diagnoses. The aim is to determine sensitivity, specificity, and predictive value of the AI tool across diverse populations and skin tones. The study will also assess user experience, accessibility, and integration into clinical care pathways.
Interventions
- Diagnostic test Smartphone-based AI skin lesion analysis (NuvanaDx platform).
Smartphone-based AI skin lesion analysis (NuvanaDx platform).
Primary outcome measures
- Diagnostic Accuracy of AI tool compared with dermatologist-confirmed diagnosis [Time frame: Time Frame: Up to 12 months]
Eligibility criteria
Inclusion criteria
Adults (≥18 years) presenting with skin lesions suspicious for malignancy.
Ability to provide informed consent.
Exclusion criteria
Inability to provide informed consent.
Poor-quality images unsuitable for AI analysis.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Ecologic or community
Study locations
United Kingdom · 1 center
- Nuvana Healthcare Ltd — London
Identifiers
NCT: NCT07144306 · 70148 · 359904